FDA Reviews Ban on Silicone Breast Implants
April 11, 2005 - The FDA is beginning a review that could see controversial silicone breast implants return to the U.S. market. Today an FDA panel heard oral presentations from the public.
The implants were banned 13 years ago except for a limited number of women participating in clinical trials. Now, two makers of the implants - Inamed and Mentor -- are trying to show the FDA that the implants have been redesigned and carry minimal health risks for women. The companies will speak before the panel on Tuesday.
But ahead of the three-day hearing, agency reviewers questioned whether the companies have enough data to show that the silicone gel-filled implants are safe in the long term.
An FDA advisory panel voted 9 to 6 in 2003 to recommend that Inamed be allowed to sell its silicone gel implants to U.S. women. An earlier version of the implants was banned in 1992 amid fears that they were prone to rupture and leakage that may lead to health problems.
But the agency went against its advisers and rejected the application, citing concerns that the company had shown that the implants can remain durable for more than a couple of years.
Concerns About Ruptures
Inamed's implants rupture in up to 21% of patients within three to four years, depending on the type of surgery used to place them, according to data submitted by the company in advance of this week's review. The implants ruptured in 3.4% of women who used them for cosmetic breast augmentation, the most common reason for surgery.
Mentor reported that its implants rupture in up to 5% of women within two to three years of surgery and in 0.5% of women who have breast augmentation.
Ruptures can lead to pain and hardness in the breasts and can also damage the appearance of the implants, according to European and American studies.
Silicone gel-filled implants have also been plagued by concerns that they can cause serious systemic health problems like lupus or even cancers. A federal judge in 1999 approved a $3.2 billion legal settlement between one-time manufacturer Dow Corning and thousands of women who claimed to have suffered adverse health consequences from their implants.